Clinical Trial Update: Spironolactone Safety in Dialysis Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating spironolactone safety in dialysis patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Heart Failure

Drugs mentioned

• Spironolactone (spironolactone)

Snippet

Sponsor: State University of New York - Upstate Medical University | Conditions: End Stage Renal Disease, Congestive Heart Failure | Phase 4 | Status: WITHDRAWN